Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the Bambuí Health Aging Study (BHAS)

Fuzikawa, A.K.; Peixoto, S.V.; Taufer, M.; Moriguchi, E.H.; Lima-Costa, M.F.

doi:10.1590/S0100-879X2008000700015

Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the Bambuí Health Aging Study (BHAS)

A.K. Fuzikawa, S.V. Peixoto, M. Taufer, E.H. Moriguchi and M.F. Lima-Costa

Pages 93-94. The correct list of REFERENCES is printed below. For html or pdf file, see:

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000200002&lng=en&nrm=iso&tlng=en

1. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984; 25: 1277-1294.
2. Kesaniemi YA, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest 1987; 80: 578-581.
3. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8: 1-21.
4. Das HK, McPherson J, Bruns GA, Karathanasis SK, Breslow JL. Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. J Biol Chem 1985; 260: 6240-6247.
5. Paik YK, Chang DJ, Reardon CA, Davies GE, Mahley RW, Taylor JM. Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci U S A 1985; 82: 3445-3449.
6. Howard BV, Gidding SS, Liu K. Association of apolipoprotein E phenotype with plasma lipoproteins in African-American and white young adults. The CARDIA Study. Coronary artery risk development in young adults. Am J Epidemiol 1998; 148: 859-868.
7. Volcik KA, Barkley RA, Hutchinson RG, Mosley TH, Heiss G, Sharrett AR, et al. Apolipoprotein E polymorphisms predict low-density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol 2006; 164: 342-348.
8. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by ApoE phenotype: a meta-analysis. J Lipid Res 1992; 33: 447-454.
9. Katsuya T, Baba S, Ishikawa K, Mannami T, Fu Y, Inamoto N, et al. Epsilon 4 allele of apolipoprotein E gene associates with lower blood pressure in young Japanese subjects: the Suita Study. J Hypertens 2002; 20: 2017-2021.
10. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994; 272: 1666-1671.
11. Jemaa R, Elasmi M, Naouali C, Feki M, Kallel A, Souissi M, et al. Apolipoprotein E polymorphism in the Tunisian population: frequency and effect on lipid parameters. Clin Biochem 2006; 39: 816-820.
12. Rastas S, Mattila K, Verkkoniemi A, Niinisto L, Juva K, Sulkava R, et al. Association of apolipoprotein E genotypes, blood pressure, blood lipids and ECG abnormalities in a general population aged 85+. BMC Geriatr 2004; 4: 1.
13. Schwanke CH, da Cruz I, Leal NF, Scheibe R, Moriguchi Y, Moriguchi EH. Analysis of the association between apolipoprotein E polymorphism and cardiovascular risk factors in an elderly population with longevity. Arq Bras Cardiol 2002; 78: 561-579.
14. Formiga F, Alia P, Navarro MA, Pujol R. Apolipoprotein e genotypes in nonagenarians. J Am Geriatr Soc 2006; 54: 1471-1473.
15. Bhavani AB, Sastry KB, Reddy NK, Padma T. Lipid profile and apolipoprotein E polymorphism in essential hypertension. Indian Heart J 2005; 57: 151-157.
16. Isbir T, Yilmaz H, Bihorac A, Akoglu E. Mild-to-moderate hypertension and apolipoprotein E gene polymorphism. Am J Hypertens 1997; 10: 827-828.
17. Li X, Du Y, Du Y, Huang X. Association of apolipoprotein E gene polymorphism with essential hypertension and its complications. Clin Exp Med 2003; 2: 175-179.
18. Niu W, Guo X, Su Y, Qiu C. Apolipoprotein E and low-density lipoprotein receptor gene polymorphisms in dyslipidemias-associated essential hypertension. J Hum Hypertens 2007; 21: 337-339.
19. Yilmaz H, Isbir T, Agachan B, Aydin M. Is epsilon4 allele of apolipoprotein E associated with more severe end-organ damage in essential hypertension? Cell Biochem Funct 2001; 19: 191-195.
20. Imazu M, Yamamoto H, Toyofuku M, Watanabe T, Okubo M, Egusa G, et al. Association of apolipoprotein E phenotype with hypertension in Japanese-Americans: data from the Hawaii-Los Angeles-Hiroshima Study. Hypertens Res 2001; 24: 523-529.
21. Scuteri A, Najjar SS, Muller D, Andres R, Morrell CH, Zonderman AB, et al. ApoE4 allele and the natural history of cardiovascular risk factors. Am J Physiol Endocrinol Metab 2005; 289: E322-E327.
22. Fuzikawa AK, Peixoto SV, Taufer M, Moriguchi EH, Lima-Costa MF. Apolipoprotein E polymorphism distribution in an elderly Brazilian population: the Bambuí Health and Aging Study. Braz J Med Biol Res 2007; 40: 1429-1434.
23. Barreto SM, Passos VM, Firmo JO, Guerra HL, Vidigal PG, Lima-Costa MF. Hypertension and clustering of cardiovascular risk factors in a community in Southeast Brazil - The Bambuí Health and Ageing Study. Arq Bras Cardiol 2001; 77: 576-581.
24. Lima-Costa MF, Barreto SM, Uchoa E, Firmo JO, Vidigal PG, Guerra HL. The Bambuí Health and Aging Study (BHAS): prevalence of risk factors and use of preventive health care services. Rev Panam Salud Publica 2001; 9: 219-227.
25. Costa MF, Uchoa E, Guerra HL, Firmo JO, Vidigal PG, Barreto SM. The Bambuí health and ageing study (BHAS): methodological approach and preliminary results of a population-based cohort study of the elderly in Brazil. Rev Saúde Pública 2000; 34: 126-135.
26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
²⁷
World Health Organization. Anatomical Therapeutical Chemical (ATC) classification index with Defined Daily Doses (DDDs). http://www.whocc.no/atcddd/indexdata base Accessed February 10, 2005.
28. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-548.
29. Wattanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2005; 149: 606-612.
30. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33.
31. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
32. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159: 702-706.

Braz J Med Biol Res, July 2008, Volume 41(7) 640-641

Correction

Braz J Med Biol Res 2008; 41(2): 89-94

Publication Dates

Publication in this collection
14 Aug 2008
Date of issue
July 2008

This work is licensed under a Creative Commons Attribution 4.0 International License.

[1] 1. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984; 25: 1277-1294.

[2] 2. Kesaniemi YA, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest 1987; 80: 578-581.

[3] 3. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8: 1-21.

[4] 4. Das HK, McPherson J, Bruns GA, Karathanasis SK, Breslow JL. Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. J Biol Chem 1985; 260: 6240-6247.

[5] 5. Paik YK, Chang DJ, Reardon CA, Davies GE, Mahley RW, Taylor JM. Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci U S A 1985; 82: 3445-3449.

[6] 6. Howard BV, Gidding SS, Liu K. Association of apolipoprotein E phenotype with plasma lipoproteins in African-American and white young adults. The CARDIA Study. Coronary artery risk development in young adults. Am J Epidemiol 1998; 148: 859-868.

[7] 7. Volcik KA, Barkley RA, Hutchinson RG, Mosley TH, Heiss G, Sharrett AR, et al. Apolipoprotein E polymorphisms predict low-density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol 2006; 164: 342-348.

[8] 8. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by ApoE phenotype: a meta-analysis. J Lipid Res 1992; 33: 447-454.

[9] 9. Katsuya T, Baba S, Ishikawa K, Mannami T, Fu Y, Inamoto N, et al. Epsilon 4 allele of apolipoprotein E gene associates with lower blood pressure in young Japanese subjects: the Suita Study. J Hypertens 2002; 20: 2017-2021.

[10] 10. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994; 272: 1666-1671.

[11] 11. Jemaa R, Elasmi M, Naouali C, Feki M, Kallel A, Souissi M, et al. Apolipoprotein E polymorphism in the Tunisian population: frequency and effect on lipid parameters. Clin Biochem 2006; 39: 816-820.

[12] 12. Rastas S, Mattila K, Verkkoniemi A, Niinisto L, Juva K, Sulkava R, et al. Association of apolipoprotein E genotypes, blood pressure, blood lipids and ECG abnormalities in a general population aged 85+. BMC Geriatr 2004; 4: 1.

[13] 13. Schwanke CH, da Cruz I, Leal NF, Scheibe R, Moriguchi Y, Moriguchi EH. Analysis of the association between apolipoprotein E polymorphism and cardiovascular risk factors in an elderly population with longevity. Arq Bras Cardiol 2002; 78: 561-579.

[14] 14. Formiga F, Alia P, Navarro MA, Pujol R. Apolipoprotein e genotypes in nonagenarians. J Am Geriatr Soc 2006; 54: 1471-1473.

[15] 15. Bhavani AB, Sastry KB, Reddy NK, Padma T. Lipid profile and apolipoprotein E polymorphism in essential hypertension. Indian Heart J 2005; 57: 151-157.

[16] 16. Isbir T, Yilmaz H, Bihorac A, Akoglu E. Mild-to-moderate hypertension and apolipoprotein E gene polymorphism. Am J Hypertens 1997; 10: 827-828.

[17] 17. Li X, Du Y, Du Y, Huang X. Association of apolipoprotein E gene polymorphism with essential hypertension and its complications. Clin Exp Med 2003; 2: 175-179.

[18] 18. Niu W, Guo X, Su Y, Qiu C. Apolipoprotein E and low-density lipoprotein receptor gene polymorphisms in dyslipidemias-associated essential hypertension. J Hum Hypertens 2007; 21: 337-339.

[19] 19. Yilmaz H, Isbir T, Agachan B, Aydin M. Is epsilon4 allele of apolipoprotein E associated with more severe end-organ damage in essential hypertension? Cell Biochem Funct 2001; 19: 191-195.

[20] 20. Imazu M, Yamamoto H, Toyofuku M, Watanabe T, Okubo M, Egusa G, et al. Association of apolipoprotein E phenotype with hypertension in Japanese-Americans: data from the Hawaii-Los Angeles-Hiroshima Study. Hypertens Res 2001; 24: 523-529.

[21] 21. Scuteri A, Najjar SS, Muller D, Andres R, Morrell CH, Zonderman AB, et al. ApoE4 allele and the natural history of cardiovascular risk factors. Am J Physiol Endocrinol Metab 2005; 289: E322-E327.

[22] 22. Fuzikawa AK, Peixoto SV, Taufer M, Moriguchi EH, Lima-Costa MF. Apolipoprotein E polymorphism distribution in an elderly Brazilian population: the Bambuí Health and Aging Study. Braz J Med Biol Res 2007; 40: 1429-1434.

[23] 23. Barreto SM, Passos VM, Firmo JO, Guerra HL, Vidigal PG, Lima-Costa MF. Hypertension and clustering of cardiovascular risk factors in a community in Southeast Brazil - The Bambuí Health and Ageing Study. Arq Bras Cardiol 2001; 77: 576-581.

[24] 24. Lima-Costa MF, Barreto SM, Uchoa E, Firmo JO, Vidigal PG, Guerra HL. The Bambuí Health and Aging Study (BHAS): prevalence of risk factors and use of preventive health care services. Rev Panam Salud Publica 2001; 9: 219-227.

[25] 25. Costa MF, Uchoa E, Guerra HL, Firmo JO, Vidigal PG, Barreto SM. The Bambuí health and ageing study (BHAS): methodological approach and preliminary results of a population-based cohort study of the elderly in Brazil. Rev Saúde Pública 2000; 34: 126-135.

[26] 26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.

[27] ²⁷
World Health Organization. Anatomical Therapeutical Chemical (ATC) classification index with Defined Daily Doses (DDDs). http://www.whocc.no/atcddd/indexdata base Accessed February 10, 2005.

[28] 28. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-548.

[29] 29. Wattanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2005; 149: 606-612.

[30] 30. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33.

[31] 31. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.

[32] 32. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159: 702-706.

Brasil

Brasil

Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the Bambuí Health Aging Study (BHAS)

Braz J Med Biol Res, July 2008, Volume 41(7) 640-641

Publication Dates